The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody.
Johnson & Johnson said on
Tuesday that it had agreed to acquire the rights to an
experimental skin disorder treatment from privately held Numab
Therapeutics for about $1.25 billion. J&J.
HBM Healthcare Investments AG / Key word: Acquisition
HBM portfolio company Yellow Jersey Therapeutics to be acquired for USD 1.25 billion
28-May-2024 / 14:01 CET/CEST
Release of an ad.
By Denny Jacob Johnson & Johnson entered into an agreement with Numab Therapeutics to acquire the global rights for bispecific antibody NM26 in an all-cash deal valued at $1.25 billion. .
Swiss biotech Numab Therapeutics announced on Tuesday that it had reached an agreement to sell its subsidiary Yellow Jersey Therapeutics to Johnson & Johnson for some $1.25 billion.In a press.